SCHEMBL955977

SCHEMBL955977

ClCCCSc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.64
MAPK1 P28482 1/20 0.64
HDAC3 O15379 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
HDAC9 Q9UKV0 1/20 0.50
HDAC5 Q9UQL6 1/20 0.50
DRD2 P14416 3/20 0.47
DRD4 P21917 3/20 0.47
DRD3 P35462 2/20 0.47
CYP1A2 P05177 4/20 0.47
CYP2D6 P10635 4/20 0.47
CYP2C19 P33261 4/20 0.47
CYP2C9 P11712 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5661129 0.96 ALDH1A1 (0.58) ALDH1A1MAPK1HDAC3HDAC4HDAC1
SCHEMBL5660852 0.96 ALDH1A1 (0.58) ALDH1A1MAPK1HDAC3HDAC4HDAC1
SCHEMBL3394436 0.93 ALDH1A1 (0.61) ALDH1A1MAPK1HDAC3HDAC4HDAC1
SCHEMBL5167895 0.87 ALDH1A1 (0.74) ALDH1A1MAPK1HDAC3HDAC4HDAC1
SCHEMBL5169003 0.87 ALDH1A1 (0.74) ALDH1A1MAPK1HDAC3HDAC4HDAC1
SCHEMBL123612 0.85 ALDH1A1 (0.70) ALDH1A1MAPK1HDAC3HDAC4HDAC1
SCHEMBL420011 0.85 ALDH1A1 (0.78) ALDH1A1MAPK1HDAC3HDAC4HDAC1
SCHEMBL1931125 0.85 ALDH1A1 (0.78) ALDH1A1MAPK1HDAC3HDAC4HDAC1
SCHEMBL9038943 0.80 ALDH1A1 (0.50) ALDH1A1MAPK1HDAC3HDAC4HDAC1
SCHEMBL7414719 0.79 HDAC3 (0.54) ALDH1A1MAPK1HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110130482-A1 Process for preparing armatic thiophenyl ketones PRETOR ROGER 2011-06-02 US claimed
EP-1799638-B1 PROCESS FOR PREPARING AROMATIC THIOPHENYL KETONES CIBA HOLDING INC (CH) 2008-07-30 EP claimed
CN-101031543-A Process for preparing aromatic thiophenyl ketones CIBA SC HOLDING AG (CH) 2007-09-05 CN claimed
EP-1799638-A1 PROCESS FOR PREPARING AROMATIC THIOPHENYL KETONES CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement (CH) 2007-06-27 EP claimed
WO-2006034966-A1 PROCESS FOR PREPARING AROMATIC THIOPHENYL KETONES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2006-04-06 WO claimed
US-11236061-B2 Xanthene-based compound and photosensitive resin composition comprising same LG CHEM, LTD. (KR) 2022-02-01 US disclosed
US-20180250308-A1 NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES WESTFALISCHE WILHELMS-UNIVERSITAT MUNSTER (DE) 2018-09-06 US disclosed
EP-3344257-A1 NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES Westfälische Wilhelms-Universität Münster (DE) 2018-07-11 EP disclosed
WO-2017036880-A1 NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES Westfälische Wilhelms-Universität Münster (DE) 2017-03-09 WO disclosed
EP-2121594-B1 QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS THERAVANCE BIOPHARMA R & D IP LLC (US) 2015-10-21 EP disclosed
US-8802856-B2 Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2014-08-12 US disclosed
US-20140051864-A1 QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS THERAVANCE, INC. (US) 2014-02-20 US disclosed
EP-0072307-A1 Piperazine derivatives of theophylline LABORATOIRES SYNTEX (FR) 1983-02-16 EP disclosed
EP-0071543-A1 Piperazine derivatives of theobromine LABORATOIRES SYNTEX (FR) 1983-02-09 EP disclosed
EP-0066415-A2 N-(arylthioalkyl)-N'-(aminoalkyl)ureas A.H. ROBINS COMPANY, INCORPORATED (US) 1982-12-08 EP disclosed
EP-0033674-A2 Piperazine derivatives of theophylline LAROCHE NAVARRON S.A. Société dite: (FR) 1981-08-12 EP disclosed
US-4127661-A VASODILATOR SERDEX - SOCIETE D'ETUDES, DE RECHERCHES, DE DIFFUSION ET D'EXPLOITATION (FR) 1978-11-28 US disclosed
US-4101670-A THIOLCARBAMATES KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 1978-07-18 US disclosed
US-4017631-A MICROBIOCIDES JANSSEN PHARMACEUTICA N.V. (BE) 1977-04-12 US disclosed
US-3991202-A ANTIMICROBIALS JANSSEN PHARMACEUTICA N.V. (BE) 1976-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130482-A1 Process for preparing armatic thiophenyl ketones ACOT7, AGPAT2, COASY ALDH1A1 1816/4885MAPK1 3795/4885HDAC3 2974/4885
US-11236061-B2 Xanthene-based compound and photosensitive resin composition comprising same RER1, TAS1R1, SUN2 ALDH1A1 1289/4885MAPK1 728/4885HDAC3 4635/4885
US-20180250308-A1 NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES GRIN1, GRIN2B, GRIN3B ALDH1A1 2771/4885MAPK1 2708/4885HDAC3 696/4885
US-20140051864-A1 QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS CHRM2, CHRM5, CHRM1 ALDH1A1 1852/4885MAPK1 1708/4885HDAC3 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.